A growing illicit pharmaceutical pipeline from India to West Africa has been uncovered through trade data analysis, revealing the export of more than 320 million synthetic opioid tablets over the past three years. According to investigative reporting by Bellingcat, in collaboration with its publishing partner Newslaundry, the shipments consist largely of tapentadol, a potent painkiller that in many West African countries has not been approved by regulators despite its increasing presence on the illegal market. The scale and structure of these exports point to a rapidly expanding transnational supply chain that is adapting to regulatory pressure and exploiting global disparities in drug control systems.
Between January 2023 and December 2025, export records analyzed from trade data provider 52wmb indicate that more than 1,400 consignments of tapentadol were shipped from India to West Africa, valued at nearly 130 million US dollars. This represents a dramatic rise compared to the previous three-year period, when exports were estimated at roughly 27 million dollars. The investigation highlights how pharmaceutical trade flows have shifted significantly in a short period, with dozens of Indian suppliers now supplying powerful opioid formulations to a region already struggling with an escalating synthetic drug crisis.
Tapentadol is described in medical literature as a painkiller significantly more potent than tramadol, a drug previously central to opioid abuse patterns in West Africa. In many of the exporting cases identified, the dosages shipped were particularly strong, with more than half of recorded pills exceeding 200 milligrams, levels not approved for use in India itself. Despite this, consignments continued to be exported at scale, raising concerns about regulatory oversight and the adequacy of export controls governing pharmaceutical distribution.
The data further shows that Sierra Leone and Ghana have emerged as primary destination points for these shipments, collectively accounting for more than 80 percent of total tapentadol exports to the region. Sierra Leone alone was listed as the destination for approximately 46 percent of shipments by value, while Ghana accounted for around 36 percent. However, experts cited in the investigation caution that destination labeling may not always reflect final consumption points, as drugs are frequently rerouted through complex trafficking networks across West Africa.
Authorities in the region have increasingly documented the consequences of this influx. In Sierra Leone, President Julius Maada Bio declared a national emergency in 2024 over widespread drug abuse, describing a mixture of synthetic opioids and other substances known locally as “kush” as a “death trap.” Law enforcement agencies have reported multiple seizures of tapentadol, including intercepted shipments near the country’s border with Guinea. Despite these efforts, officials acknowledge that enforcement capacity remains limited in the face of evolving trafficking methods.
In Ghana, the Narcotics Control Commission has recorded a steady rise in tapentadol trafficking since 2022, noting that criminal networks have shifted to alternative synthetic opioids following crackdowns on tramadol. Authorities have seized millions of tablets, many traced back to India, and report that traffickers are increasingly using commercial shipping routes and courier services to conceal shipments. Drugs are often misdeclared as legitimate pharmaceutical products or even unrelated goods such as household items and electrical equipment, highlighting the sophistication of concealment strategies.
According to Ghana’s Food and Drugs Authority, no official permits have been issued for the import or manufacture of tapentadol in any strength, suggesting that all detected shipments are unauthorized. The agency also noted that Ghana has increasingly become both a destination and transit hub for the drug, with some consignments likely intended for onward movement to neighboring countries including Niger, Mali, Burkina Faso, and Nigeria. This pattern reflects a broader regional distribution network that extends beyond national borders.
The investigation also situates the trade within a broader context of regulatory adaptation and exploitation. Experts cited by Bellingcat note that drug traffickers frequently adjust to changes in enforcement regimes. Following stricter controls on tramadol exports from India in 2018, traffickers are believed to have shifted toward alternative synthetic opioids such as tapentadol, tafrodol, and combination drugs. This substitution effect has been documented by international monitoring bodies, including the International Narcotics Control Board, which warned in 2021 that new opioids were increasingly being routed toward African markets.
Previous reporting, including a BBC investigation referenced in the current analysis, has also highlighted illegal exports of opioid combinations from Indian pharmaceutical companies to West Africa. In response to earlier cases, Indian regulators banned certain drug combinations, including tapentadol mixed with carisoprodol. However, the latest findings suggest that despite regulatory interventions, the broader flow of single-ingredient tapentadol has continued to expand significantly.
India’s pharmaceutical export sector, now valued at more than 30 billion dollars annually, operates under a system that requires exporters to obtain clearance certificates confirming approval in destination countries when exporting non-domestically approved dosages. However, publicly available regulatory data indicates that tapentadol is not approved for use in the West African countries identified in the investigation, raising questions about how export permissions are being granted and verified. Bellingcat reports that the regulatory authority, the Central Drugs Standard Control Organisation, did not respond to inquiries regarding the oversight process.
The investigation also identifies structural weaknesses within regulatory frameworks that may facilitate diversion. Experts cited in the report argue that gaps in cross-border verification systems allow both legitimate pharmaceutical companies and smaller operators to export high-risk medications without effective end-use monitoring. In some cases, individuals with no traditional pharmaceutical background have been linked to multi-million-dollar shipments, further complicating enforcement efforts.
On the receiving end, West African health systems are struggling to manage the consequences of widespread synthetic opioid abuse. Medical professionals describe rising addiction rates, limited access to regulated pain relief medications, and increasing links between opioid misuse and broader public health and security challenges. In Nigeria, clinicians report that weak institutional capacity, corruption risks, and under-resourced customs agencies all contribute to the ease with which illicit pharmaceuticals enter local markets.
Experts emphasize that Africa’s opioid crisis is not uniform but varies significantly by region, shaped by differences in governance capacity, border security, and healthcare infrastructure. However, a common pattern is the imbalance between the availability of illegal synthetic opioids and the limited access to legitimate pain management drugs, which further fuels informal and illicit consumption channels.
The investigation ultimately paints a picture of a rapidly evolving transnational drug economy in which regulatory fragmentation is exploited by adaptive trafficking networks. As Bellingcat notes, the growing flow of tapentadol from India to West Africa reflects not only criminal innovation but also systemic vulnerabilities in global pharmaceutical governance. Without stronger coordination between exporting and importing countries, experts warn that the region’s opioid crisis is likely to deepen further, with synthetic drugs continuing to move along increasingly sophisticated and difficult-to-detect routes.
